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Twenty years ago, malaria was reputed to cause a million deaths a year, a figure that was 
cited widely, although this was no more than an informed guess. However, when improved 
methods for measuring malaria mortality were developed, it seemed that this figure was 
probably approximately correct.  WHO now estimates that in 2015 there were  429,000 
(uncertainty interval 235-639,000) deaths from malaria, and 212 (uncertainty interval 148-
394) million cases of malaria, declines of approximately  62% and 41% respectively during 
the past 15 years.1  The key to this success has been a remarkable  increase in funding for 
malaria control, both from the international donor community and from malaria affected 
countries, from a few hundred million dollars in 2000 to $2.9 billion  in 2015.1  This increase 
in funding has allowed a massive scaling up of control tools that were already available a 
decade ago, namely insecticide treated bednets (ITNs), rapid diagnostic tests (RDTs) and 
artemisinin combination therapy (ACT).  A recent study suggests that scaling up of ITNs has 
accounted for 68% % of the reduction in  cases of malaria  seen during the period 2000 to 
2015, with RDTs and ACT accounting for 22 % and Indoor Residual Spraying (IRS) for a 
further 10%.2 Use of currently available tools has led to elimination of malaria, defined as 
interruption of local transmission of malaria, in 17 countries, including Sri Lanka, during the 
past 15 years.1   
Reduction in the burden of malaria by around a half during a 15-year period is a remarkable 
global health success. However, addressing the remaining half faces a number of major 
challenges. Firstly, there is the challenge of sustaining national and international funding for 
malaria control at a time of political uncertainty and declining malaria incidence.   Secondly, 
there is political instability in some of the areas where malaria transmission remains high, 
making effective control difficult or impossible to achieve. Finally, there is the threat posed 
by the potential emergence and spread of artemisinin-resistant Plasmodium falciparum 
parasites in sub-Saharan Africa and by the rapidly increasing resistance of malaria vectors to 
the pyrethroid insecticides employed in ITNs.   There is strong evidence that the emergence 
and spread of chloroquine-resistant P. falciparum towards the end of the last century led to 
a marked increase in deaths from malaria, an increase that the global health community was 
slow to recognise.3 Consequently,  there are legitimate concerns that the spread of parasites 
resistant to artemisinins from Asia to Africa,4 or local emergence of resistant parasites in 
Africa, will have an impact on malaria mortality similar to the one seen following the 
emergence of chloroquine resistance. However, although the emergence of artemsinin-
resistant parasites in Africa would be a setback, this would probably be less damaging than 
was the emergence and spread of chloroquine resistance for several reasons. Firstly, there is 
now wider recognition of the importance of on-going surveillance for drug resistance, and 
secondly development of molecular methods for measuring resistance has made this easier 
to follow than was the case in the past.5 Finally, there has been wise investment in the 
development of new anti-malarial drugs before, rather than after, they are needed to deal 
with resistant parasites. Through the work of organisations such as the Medicines for 
Malaria Venture, a promising range of antimalarial drugs with novel modes of action, 
including those that have transmission blocking activities, has been developed and several 
of these drugs are in clinical trials. There is a good chance that one or more of these drugs 
would be available for clinical use should artemisinins-resistant parasites appear and spread 
in Africa in the next few years.  The emergence and spread of anopheline mosquitoes 
resistant to the pyrethroid group of insecticides used in ITNs is probably  a greater threat to 
malaria control than drug resistance.6   Development and evaluation of novel insecticides for 
use in IRS and in ITNs is difficult and expensive and perhaps more challenging than 
development of new antimalarial drugs. Although progress is being made in this field 
through organisations such as the Innovative Vector Control consortium, there is a risk that 
there will be a gap between the failure of pyrethroid-impregnated nets, currently the most 
important of current malaria control tools, and an effective replacement.      
Although further, intensified efforts at scaling up current malaria control interventions may 
provide some further gains, it is unlikely that elimination of malaria will be achieved in high 
transmission areas without the employment of additional tools.   The two interventions 
most likely to fill this gap are a malaria vaccine and/or some form of genetically modified 
mosquitoes, although there may be a role for other vector control interventions, such as 
larviciding, in some limited situations. Developing a malaria vaccine has been challenging 
but one partially effective malaria vaccine (RTS,S/AS01) has achieved a positive opinion from 
a regulatory authority7 and will now  be deployed in  three large-scale pilot projects. The 
development of  vaccines based on irradiated or genetically modified sporozoites is also 
making good progress.8  Genetic modification of anopheline mosquitoes making them 
unable to reproduce or genetically resistant to malaria, and driving these modified 
mosquitoes through the population, has for many years seemed an impossible dream but 
recent development in molecular biology, including development of the CRISP/cas9 gene 
editing technique, have the potential to transform this dream into a reality. Although there 
are many safety and ethical challenges to be met, this approach to malaria control is 
becoming a realistic option.9     
An advantage of ITNs as a malaria control tool has been the fact that in sub-Saharan Africa 
nearly all malaria is transmitted by night-biting mosquitoes. Thus, it was possible to 
recommend and deploy this intervention across the continent.  This universality of approach 
is not likely to apply to many of the new interventions under development or recently 
deployed. For example deployment of Seasonal Malaria Chemoprevention (SMC) is 
restricted to the areas of the Sahel and sub-Sahel of Africa where malaria transmission is 
limited to a few months each year.10 It is important that deployment of the new tools 
emerging in the coming years is also based on a careful match between the properties of 
the intervention and knowledge of the local epidemiology of malaria. Ensuring that this 
happens will need an expansion in the number of well-trained scientists from endemic 
countries in the many disciplines that will be needed to achieve malaria elimination in high 
transmission areas.    
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